Gain Therapeutics, Inc. GANX
Set alert
1.13 USD -0.06 -5.04%
At close · Oct 30
1.16 +0.03 +2.45%
After hours · Oct 30, 5:47 PM ET
1.11 Day range 1.20
1.13 52-week range 4.18
- YTD
- -64.91%
- 1 year
- -35.80%
- Open
- 1.18
- Prev close
- 1.19
- Mkt cap
- 49.32M
- Vol
- 364.65K
- Avg vol
- 501.79K
- EPS
- -0.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.11
- High
- 1.20
- Forward P/E
- -1.76
- Beta
- 0.34
- Short ratio
- 1.65
- Inst. own
- 7.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.05
- 200-d avg
- 2.12
- 1y target
- 7.33
2Y chart
Events in this range
- Nov 14, 2024Earnings: -0.17; estimate -0.23; surprise 26.09%
- Nov 25, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 5, 2024Rating: Roth MKM · — → Buy
Signals (118)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 2 days ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 29, 2026 | 3 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 22, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 9, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 14, 2026 | 6 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 16, 2026 | 7 months ago |
| SMA: Bullish | Feb 24, 2026 | 8 months ago |
| RSI: Overbought | Feb 24, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 29, 2026 | 9 months ago |
| SMA: Bearish | Jan 15, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 9 months ago |
| SMA: Bullish | Dec 19, 2025 | 10 months ago |
| SMA: Bearish | Dec 18, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 18, 2025 | 10 months ago |
| RSI: Overbought | Dec 5, 2025 | 11 months ago |
| RSI: Overbought | Nov 28, 2025 | 11 months ago |
| RSI: Overbought | Nov 11, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Nov 6, 2025 | 12 months ago |
| SMA: Bullish | Nov 6, 2025 | 12 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 16, 2025 | 1 year ago |
| SMA: Bearish | Oct 15, 2025 | 1 year ago |
| SMA: Bullish | Oct 14, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| RSI: Overbought | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 3, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 26, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 19, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| SMA: Bearish | Sep 12, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Sep 4, 2025 | 1 year ago |
| SMA: Bullish | Aug 29, 2025 | 1 year ago |
| SMA: Bearish | Aug 27, 2025 | 1 year ago |
| SMA: Bullish | Aug 26, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| SMA: Bullish | Aug 15, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 12, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 11, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 25, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 25, 2025 | 1 year ago |
| SMA: Bearish | Jun 11, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Sell Signal | May 20, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 16, 2025 | 1 year ago |
| MACD: Sell Signal | May 14, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bullish | May 8, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | Apr 30, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 16, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 28, 2025 | 1 year ago |
| SMA: Bearish | Mar 26, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 13, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 20, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 22, 2025 | 1 year ago |
| RSI: Overbought | Jan 6, 2025 | 1 year ago |
| RSI: Oversold | Dec 3, 2024 | 1 year ago |
| RSI: Oversold | Nov 26, 2024 | 1 year ago |
Key statistics
- Market cap
- 41.64M
- Enterprise value
- 30.98M
- Trailing P/E
- 0.00
- Forward P/E
- -1.76
- PEG ratio
- 0.00
- Price / book
- 2.02
- EPS (TTM)
- -1.07
- Beta
- 0.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -10.06M
- Total cash
- 16.94M
- Total debt
- 807.57K
- Return on equity
- -188.83%
- Shares outstanding
- 26.53M
- Short % of float
- 2.71%
- 50-day average
- 2.05
- 200-day average
- 2.12
Analyst view
Consensus: none
Price target (mean) 7.33 +549.0% upside
Now 1.13
- Target (low)
- 5.00
- Target (mean)
- 7.33
- Target (high)
- 10.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.17333.
Financials — quick view
GANX Revenue — quarterly 0
GANX Net income — quarterly -4.68M
GANX EPS — quarterly -0.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.23 | -0.17 | +0.06 | +26.09% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | -0.42 | -0.11 | -35.48% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.30 | -0.22 | +0.08 | +26.67% |
| May 14, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| Mar 26, 2024 | Dec 1, 2023 | -0.32 | -0.29 | +0.03 | +9.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | init | — | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 9, 2024 | Chardan Capital | main | Buy | Buy |
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gaintherapeutics.com
News
- Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
- Gain Therapeutics to Attend the 2026 Maxim Growth Summit
- HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
- Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract
- Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
- Gain Therapeutics Reveals Poster Presentation At International Congress Of Parkinson’s Disease and Movement Disorders
- Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders
- Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison
- Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
- HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
Your note
Sign in to keep a note on GANX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALDER MATTHIAS | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 25, 2024 | 21,140 |
| ISLAM KHALID | Officer and Director | Purchase | Aug 8, 2024 | 930,784 |
| MACK GENE C | Chief Executive Officer | Purchase | Aug 8, 2024 | 14,400 |
| RICHMAN ERIC I. | Director | Purchase | Jun 30, 2024 | 304,458 |
| RILEY JEFFREY SCOTT | Director | Purchase | Mar 27, 2024 | 30,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| DME Capital Management, LP | 2.13% | 566,130 | 888.82K | Sep 29, 2024 |
| Gotham Asset Management, LP | 1.26% | 334,592 | 525.31K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.03% | 271,972 | 427.00K | Sep 29, 2024 |
| Vanguard Group Inc | 0.55% | 145,217 | 227.99K | Sep 29, 2024 |
| Blackrock Inc. | 0.32% | 84,924 | 133.33K | Sep 29, 2024 |
| Jones Financial Companies, L.L.L.P. | 0.20% | 53,500 | 84.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.54% | 143,522 | 225.33K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.51% | 135,702 | 213.05K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.21% | 56,624 | 88.90K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 38,783 | 60.89K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 34,738 | 54.54K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 10,062 | 15.80K | Oct 30, 2024 |